The transaction represents a 36% premium over Bio-Techne’s one-month volume-weighted average trading price and is expected to close by late 2026 or early 2027. By absorbing Bio-Techne’s portfolio of recombinant proteins, immunoassay kits, and automated analytical instruments, Merck KGaA aims to deepen its reach across the entire scientific value chain, from early-stage discovery to commercial manufacturing.

Kai Beckmann, Chairman of the Executive Board and Group CEO of Merck KGaA, noted that the acquisition aligns with the company’s strategic push into next-generation biology. Beyond expanding its product offerings, the company anticipates annual cost synergies of approximately EUR 140 million to be fully realized within three years of closing. The acquisition, which has received board approval from both companies, will be financed through a mix of existing cash and new debt.